Expert Interview
A Second Look at setrusumab (UX143) for the treatment of osteogenesis imperfecta ahead of the Phase 3 randomized, placebo-controlled readout
Ticker(s): RARE, MREOInstitution: University Hospital Cologne
- Head of the Center for Rare Skeletal Disorders in Children and Adolescents at the University of Cologne & member of the Osteogenesis Imperfecta Federation Europe (OIFE) Medical Advisory Board
- Treats 52 patients with Achondroplasia older than 5 years of age and is currently prescribing Voxzogo to 26 patients.
- Specializes in the research of brittle bone disease and directs the special ambulance for rare pediatric skeletal diseases and pediatric rheumatology.
How would you compare the mechanism of action of setrusumab, as an anti-sclerostin antibody, to current standards of care such as bisphosphonates or teriparatide in pediatric and young adult OI patients?
Added By: sara_adminWhat data from the Phase 3 portion of the ORBIT study would be most important for you when considering setrusumab for routine clinical use?
Added By: sara_adminWhat unmet needs remain in the management of OI across different subtypes and age groups, and how do you see a therapy like setrusumab potentially changing long-term care?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
